Barclays
TCRT icon

Barclays’s Alaunos Therapeutics TCRT Stock Holding History

Barclays’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50
Closed -$121 – 5676
2025
Q3 		$121 Sell
50
-50
-50% -$143 ﹤0.01% 5264
2025
Q2 		$485 Sell
100
-71
-42% -$214 ﹤0.01% 5078
2025
Q1 		$251 Buy
+171
New +$280 ﹤0.01% 5112
2022
Q4 		– Sell
-908
Closed -$234K – 5369
2022
Q3 		$234K Buy
+908
New +$264K ﹤0.01% 3118
2022
Q2 		– Sell
-234
Closed -$24K – 5263
2022
Q1 		$24K Sell
234
-1,462
-86% -$188K ﹤0.01% 4394
2021
Q4 		$278K Buy
1,696
+1,117
+193% +$245K ﹤0.01% 3451
2021
Q3 		$158K Buy
579
+379
+190% +$116K ﹤0.01% 3729
2021
Q2 		$80K Sell
200
-1,004
-83% -$469K ﹤0.01% 3938
2021
Q1 		$650K Buy
1,204
+727
+152% +$453K ﹤0.01% 3039
2020
Q4 		$180K Sell
477
-173
-27% -$68.8K ﹤0.01% 3820
2020
Q3 		$245K Sell
650
-149
-19% -$65.8K ﹤0.01% 3717
2020
Q2 		$393K Buy
799
+367
+85% +$164K ﹤0.01% 3541
2020
Q1 		$158K Sell
432
-837
-66% -$433K ﹤0.01% 4474
2019
Q4 		$898K Buy
1,269
+101
+9% +$69.5K ﹤0.01% 3770
2019
Q3 		$751K Sell
1,168
-743
-39% -$589K ﹤0.01% 3915
2019
Q2 		$1.67M Buy
1,911
+677
+55% +$466K ﹤0.01% 3131
2019
Q1 		$713K Buy
1,234
+690
+127% +$288K ﹤0.01% 3776
2018
Q4 		$152K Sell
544
-409
-43% -$162K ﹤0.01% 4774
2018
Q3 		$457K Buy
953
+719
+307% +$308K ﹤0.01% 4347
2018
Q2 		$106K Buy
234
+52
+29% +$33K ﹤0.01% 5203
2018
Q1 		$106K Sell
182
-358
-66% -$223K ﹤0.01% 5342
2017
Q4 		$335K Buy
540
+145
+37% +$104K ﹤0.01% 4234
2017
Q3 		$364K Buy
395
+391
+9,775% +$347K ﹤0.01% 3905
2017
Q2 		$5K Sell
4
-24
-86% -$23.5K ﹤0.01% 6247
2017
Q1 		$26K Sell
28
-324
-92% -$302K ﹤0.01% 5689
2016
Q4 		$283K Buy
352
+183
+108% +$165K ﹤0.01% 3899
2016
Q3 		$142K Buy
169
+168
+16,800% +$135K ﹤0.01% 4248
2016
Q2 		$1K Sell
1
-88
-99% -$95.8K ﹤0.01% 6165
2016
Q1 		$94K Buy
89
+88
+8,800% +$90.1K ﹤0.01% 4397
2015
Q4 		$1K Sell
1
-46
-98% -$76.1K ﹤0.01% 5853
2015
Q3 		$63K Sell
47
-17
-27% -$28.1K ﹤0.01% 4890
2015
Q2 		$115K Buy
64
+45
+237% +$69.9K ﹤0.01% 4569
2015
Q1 		$28K Sell
19
-1,926
-99% -$2.85M ﹤0.01% 5653
2014
Q4 		$1.46M Buy
1,945
+722
+59% +$383K ﹤0.01% 2817
2014
Q3 		$366K Sell
1,223
-1,121
-48% -$540K ﹤0.01% 4225
2014
Q2 		$1.41M Sell
2,344
-4,569
-66% -$2.54M ﹤0.01% 2984
2014
Q1 		$4.15M Sell
6,913
-2,402
-26% -$1.61M ﹤0.01% 1854
2013
Q4 		$5.59M Buy
9,315
+2,794
+43% +$1.66M 0.01% 1737
2013
Q3 		$2.93M Buy
6,521
+2,581
+66% +$1.16M ﹤0.01% 2174
2013
Q2 		$1.25M Buy
+3,940
New +$1.09M ﹤0.01% 3092

Other funds holding TCRT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Barclays's TCRT Position: Q4 2025 in Review

Barclays sold out of Alaunos Therapeutics (TCRT) in Q4 2025, closing a stake of 50 shares — an estimated $121 sold.

Barclays first reported a position in TCRT in Q2 2013 and held it in 40 quarters. The position peaked at $5.59M in Q4 2013. 27 funds tracked by Wall St. Rank hold TCRT as of Q4 2025.

  • Barclays reported no remaining Alaunos Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Barclays sold 50 Alaunos Therapeutics shares in Q4 2025, an estimated $121.
  • Barclays first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 40 quarters.
  • Barclays's Alaunos Therapeutics position peaked at $5.59M in Q4 2013.
  • 27 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.